Avilés A, Díaz-Maqueo J C, Torras V
Departamento de Hematología, Hospital de Oncología, Centro Médico Nacional, I.M.S.S., México, D.F.
Rev Invest Clin. 1990 Apr-Jun;42(2):99-102.
Eighteen patients with advanced malignant lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of cisplatinum, vinblastine and bleomycin. Ten patients (55%) responded (two complete remissions and eight partial). The median survivaL time of patients responding was 15 weeks which was better that the one in patients with no response (3 weeks). Toxicity was mild. We believe that the use of cisplatinum could be useful in patients with refractory malignant lymphoma in combination with other drugs.
18例对先前化疗耐药的晚期恶性淋巴瘤患者接受了由顺铂、长春碱和博来霉素组成的联合化疗。10例患者（55%）有反应（2例完全缓解，8例部分缓解）。有反应患者的中位生存时间为15周，优于无反应患者（3周）。毒性较轻。我们认为，顺铂与其他药物联合使用可能对难治性恶性淋巴瘤患者有用。
